Bayer (BAYN) Wins FDA Approval for SUNHARBO After Stroke Rate Fell to 6.2% vs 8.4%
Bayer (BAYN) received FDA approval for SUNHARBO, a Factor XIa inhibitor, to reduce stroke risk. Phase 3 trial data showed a 6.2% stroke rate with SUNHARBO vs. 8.4% with placebo. The drug is approved for secondary stroke prevention and is expected to ship in the U.S. in mid-to-late November. China approved it on October 26, 2026.
How this was made

The 30-second read
Why it matters
The approval creates a new revenue stream for Bayer and may influence peer biotech valuations.
Market read
First U.S. approval for a novel stroke‑prevention drug, likely to move Bayer shares and affect the anticoagulant sector.
What to watch
Pricing, reimbursement negotiations, and competition from existing antiplatelet drugs could limit upside.
Background
Bayer announced FDA approval of its experimental Factor XIa inhibitor SUNHARBO after a Phase 3 trial showed a 26% relative risk reduction in ischemic stroke.
Ticker impact
FDA approval of Bayer's SUNHARBO for secondary stroke prevention, first U.S. approval of the drug.
likely upside as investors price in future sales of SUNHARBO
Regulatory clearance removes a major hurdle; the drug targets a large market and has favorable Phase 3 data.
Market effects
May boost the broader anticoagulant/antiplatelet sector as a new Factor XIa inhibitor enters the market.
U.S. biotech stocks could see modest gains on the news.
Adds a new approved therapy to the global stroke‑prevention market.
Counterpoint
If commercial uptake is slower than expected, the approval may not translate into meaningful revenue.
Key entities
- CompanyBayer AG
German pharmaceutical giant, ticker BAYRY (ADR).
